Who makes LOR-253 HCl?

LOR-253 HCl is developed by Aptose Biosciences Inc..

Last reviewed 2026-04-19 · How we verify

LOR-253 HCl

Aptose Biosciences Inc. · Phase 1 active Small molecule

At a glance

Generic name	LOR-253 HCl
Also known as	No other names are used.
Sponsor	Aptose Biosciences Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LOR-253 HCl CI brief — competitive landscape report
LOR-253 HCl updates RSS · CI watch RSS
Aptose Biosciences Inc. portfolio CI